2,618 Shares of Danaher Corporation $DHR Purchased by Consilium Wealth Advisory LLC

Consilium Wealth Advisory LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,618 shares of the conglomerate’s stock, valued at approximately $580,000.

Several other institutional investors and hedge funds also recently bought and sold shares of DHR. Marquette Asset Management LLC lifted its position in shares of Danaher by 192.1% in the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 73 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new stake in shares of Danaher during the second quarter worth approximately $25,000. Main Street Group LTD acquired a new stake in shares of Danaher during the first quarter worth approximately $25,000. Field & Main Bank purchased a new position in Danaher during the second quarter valued at approximately $29,000. Finally, Evolution Wealth Management Inc. grew its position in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.6%

NYSE DHR traded up $1.44 during trading on Wednesday, reaching $224.28. The company’s stock had a trading volume of 1,890,805 shares, compared to its average volume of 4,448,106. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $157.66 billion, a PE ratio of 39.79, a PEG ratio of 2.78 and a beta of 0.76. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The business has a 50-day moving average price of $212.41 and a 200-day moving average price of $195.13.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.77 EPS. On average, research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Guggenheim upped their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Evercore reissued an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. The Goldman Sachs Group boosted their price target on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Wells Fargo & Company lowered their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Finally, Stifel Nicolaus dropped their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $235.41.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.